You Should Consider Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Because Of These Reasons
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) due to its excellent fundamentals in more than one area. VRTX is a company with impressive financial health as well as an optimistic growth outlook. In the following section, I expand a bit more on these key aspects. If you’re interested in understanding beyond my high-level commentary, take a look at the report on Vertex Pharmaceuticals here.
Exceptional growth potential with flawless balance sheet
VRTX is financially robust, with ample cash on hand and short-term investments to meet upcoming liabilities. This suggests prudent control over cash and cost by management, which is a key determinant of the company’s health. VRTX seems to have put its debt to good use, generating operating cash levels of 1.4x total debt in the most recent year. This is also a good indication as to whether debt is properly covered by the company’s cash flows.
Next Steps:
For Vertex Pharmaceuticals, I’ve put together three pertinent factors you should further research:
Historical Performance: What has VRTX’s returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
Valuation: What is VRTX worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether VRTX is currently mispriced by the market.
Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of VRTX? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.
